John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Ezra Klein Show: Jensen Huang Thinks A.I. Alarmism Has Gone Too Far 1h 50m · 25 Sep 2026 · Hard Fork

Pretty Little Episode #110 26 min · 25 Sep 2026 · Handsome

Be Upfront About How You Make Money From Your Podcast 2 min · 25 Sep 2026 · One Minute Podcast Tips - Be a Better Podcaster in Just 60 Seconds

High Stakes US-China Sit Down & Flock Surveillance Under Scrutiny | 9.25.26 19 min · 25 Sep 2026 · Morning Wire

Ireland collapse in Kosovo as Israel game looms 13 min · 25 Sep 2026 · Today with David McCullagh

Living Breakthrough-Minded | Joel Osteen 30 min · 25 Sep 2026 · Joel Osteen Podcast

Report any issue

Source

Recorded31 Aug 2026

Publisheraudiomedica.com ↗

Handlerec:20198998

Show notes

CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncology.Peter Goodwin got the details from first author John Mascarenhas MD, Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Tisch Cancer Institute, Icahn School of Medicine, in Mount Sinai, New York, NY.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in